Literature DB >> 31157582

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Antonio C Wolff1, Nadine M Tung2, Lisa A Carey3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31157582     DOI： 10.1200/JCO.19.01159

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.

Authors:  Gabrielle B Rocque; Nicole E Caston; Jeffrey A Franks; Courtney P Williams; Monica S Aswani; Andres Azuero; Risha Gidwani
Journal:  Breast Cancer Res Treat       Date:  2021-09-29       Impact factor: 4.872

2.  Immunotherapy for Breast Cancer Treatment.

Authors:  Miganoosh Simonian; Mozhan Haji Ghaffari; Babak Negahdari
Journal:  Iran Biomed J       Date:  2021-03-08

3.  Patient perspectives on chemotherapy de-escalation in breast cancer.

Authors:  Gabrielle B Rocque; Courtney P Williams; Courtney Andrews; Timothy C Childers; Kimberly D Wiseman; Kathleen Gallagher; Nadine Tung; Alan Balch; Valerie M Lawhon; Stacey A Ingram; Thelma Brown; Tara Kaufmann; Mary L Smith; Angela DeMichele; Antonio C Wolff; Lynne Wagner
Journal:  Cancer Med       Date:  2021-05-01       Impact factor: 4.452

4.  Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.

Authors:  Courtney Andrews; Timothy C Childers; Kimberly D Wiseman; Valerie Lawhon; Stacey Ingram; Mary Lou Smith; Antonio C Wolff; Lynne Wagner; Gabrielle B Rocque
Journal:  BMC Cancer       Date:  2022-02-04       Impact factor: 4.430

5.  NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer.

Authors:  Yuan Yuan; Huanyao Gao; Yongxian Zhuang; Lixuan Wei; Jia Yu; Zhe Zhang; Lili Zhang; Liewei Wang
Journal:  Ther Adv Med Oncol       Date:  2021-06-30       Impact factor: 8.168
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.